Drug trial changes will make UK one of world's best places for research

hl.co.uk:

We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Newsroom

Newsroom articles are published by leading news agencies. Hargreaves Lansdown is not responsible for an article's content and its accuracy. We may not share the views of the author.

HL Podcast

HL Insight

Medical advances now mean the prognoses for many of the most serious diseases are significantly improving — the chances of surviving cancer, for example, are now double those of 50 years ago.

Article originally published by The Telegraph. Hargreaves Lansdown is not responsible for its content or accuracy and may not share the author's views. News and research are not personal recommendations to deal. All investments can fall in value so you could get back less than you invest.

Published by

14 Nov 2023

These medical advances would not have been possible without clinical trials. As well as speeding up patient access to cutting-edge treatments, we know that trials lead to better care outcomes for participants overall. They also bring with them significant investment in the economy.

Earlier this year, the Government commissioned an independent review, led by Lord O’Shaughnessy, into the UK commercial clinical trials landscape, to help unlock growth and investment opportunities and tackle some of the key challenges facing the sector.

One of the challenges we have faced is the impact of the pandemic. This resulted initially in a sharp decline in approvals for non-Covid clinical trials, and more recently to increased demand as UK researchers have sought to build on the success of Covid research – leading to a backlog.

Thanks to the concerted efforts of the